HIV Clinical Trial
— OHARTOfficial title:
The Impact of Oral Health on Metabolism and Persistent Inflammation in HIV Patients on Antiretroviral Therapy
This is a prospective cohort study designed to investigate the range of metabolic abnormalities observed in patients living with HIV on antiretroviral therapy. This study will also explore the concurrent role of poor oral health in supporting and driving chronic immune activation and inflammation in HIV infection.
Status | Recruiting |
Enrollment | 350 |
Est. completion date | March 2025 |
Est. primary completion date | March 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age =18 years - Has been diagnosed with HIV (as documented by a prior laboratory report of positive HIV-1/2 antibody and/or detectable HIV RNA, available for review by the study team) - Has received antiretroviral therapy for at least 12 months - Able and willing to provide informed consent prior to initiation of study procedures - Willing and able to comply with all study procedures, and likely to be available for the duration of the study Exclusion Criteria: - Has been diagnosed with the following xerostomia-related autoimmune conditions: Sjorgen's and sarcoidosis - Has never received radiation therapy to the head or neck (including radioactive iodine therapy) - Was taking anti-osteoporotic agents (biphosphonates, denosumab) prior to HIV diagnosis. - Women who are pregnant at the time of enrollment. |
Country | Name | City | State |
---|---|---|---|
United States | University of Pennsylvania School of Dental Medicine | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
University of Pennsylvania | National Institute of Dental and Craniofacial Research (NIDCR) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Dental Caries as assessed by DMFS Score | Decayed, missing and filled surfaces (DMFS) score to assess dental caries. Minimum value is 0 and maximum value is 128 for 28 teeth. Higher scores mean higher levels of dental decay. | Baseline | |
Primary | Dental Caries as assessed by DMFS Score | Decayed, missing and filled surfaces (DMFS) score to assess dental caries. Minimum value is 0 and maximum value is 128 for 28 teeth. Higher scores mean higher levels of dental decay. | 6 months after baseline visit | |
Primary | Dental Caries as assessed by DMFS Score | Decayed, missing and filled surfaces (DMFS) score to assess dental caries. Minimum value is 0 and maximum value is 128 for 28 teeth. Higher scores mean higher levels of dental decay. | 12 months after baseline visit | |
Primary | Dental Caries as assessed by DMFS Score | Decayed, missing and filled surfaces (DMFS) score to assess dental caries. Minimum value is 0 and maximum value is 128 for 28 teeth. Higher scores mean higher levels of dental decay. | 18 months after baseline visit | |
Primary | Dental Caries as assessed by DMFS Score | Decayed, missing and filled surfaces (DMFS) score to assess dental caries. Minimum value is 0 and maximum value is 128 for 28 teeth. Higher scores mean higher levels of dental decay. | 24 months after baseline visit | |
Primary | Dental Caries as assessed by DMFS Score | Decayed, missing and filled surfaces (DMFS) score to assess dental caries. Minimum value is 0 and maximum value is 128 for 28 teeth. Higher scores mean higher levels of dental decay. | 30 months after baseline visit | |
Primary | Periodontal disease | Incidence of periodontal disease | Baseline | |
Primary | Periodontal disease | Incidence of periodontal disease | 12 months after baseline visit | |
Primary | Periodontal disease | Incidence of periodontal disease | 24 months after baseline visit | |
Primary | Periodontal disease | Incidence of periodontal disease | 30 months after baseline visit | |
Primary | Oral mucosal lesions coinfection as assessed by the presence or absence of candidiasis, red/white lesions, ulcers and warts intraorally | Prescence or absence of warts, red or white lesions and candidia | Baseline | |
Primary | Oral mucosal lesions coinfection as assessed by the presence or absence of candidiasis, red/white lesions, ulcers and warts intraorally | Prescence or absence of warts, red or white lesions and candidia | 6 months after baseline visit | |
Primary | Oral mucosal lesions coinfection as assessed by the presence or absence of candidiasis, red/white lesions, ulcers and warts intraorally | Prescence or absence of warts, red or white lesions and candidia | 12 months after baseline visit | |
Primary | Oral mucosal lesions coinfection as assessed by the presence or absence of candidiasis, red/white lesions, ulcers and warts intraorally | Prescence or absence of warts, red or white lesions and candidia | 18 months after baseline visit | |
Primary | Oral mucosal lesions coinfection as assessed by the presence or absence of candidiasis, red/white lesions, ulcers and warts intraorally | Prescence or absence of warts, red or white lesions and candidia | 24 months after baseline visit | |
Primary | Oral mucosal lesions coinfection as assessed by the presence or absence of candidiasis, red/white lesions, ulcers and warts intraorally | Prescence or absence of warts, red or white lesions and candidia | 30 months after baseline visit | |
Primary | Osteopenia as assessed by DXA scan findings | Incidence of osteopenia | Baseline | |
Primary | Osteopenia as assessed by DXA scan findings | Incidence of osteopenia | 24 months after baseline visit | |
Primary | Quality of life as assessed by the Xerostomia Quality of Life Scale (XeQoLS) | The XeQoLS consists of 15 questions. The first 14 questions assess how dryness in the mouth impacts the individual's life, with answer options of "not at all," "a little," "somewhat," "quite a bit," and "very much." The final question asks "if you were to spend the rest of your life with your dry mouth/throat dryness just the way it is now, how would you feel about this?" and includes options ranging from "delighted" to "terrible." All 15 questions can be translated to a score of 0-4, with a score of 4 indicating the most dry mouth-related problems and 0 indicating no dry mouth-related problems. | Baseline | |
Primary | Quality of life as assessed by the Xerostomia Quality of Life Scale (XeQoLS) | The XeQoLS consists of 15 questions. The first 14 questions assess how dryness in the mouth impacts the individual's life, with answer options of "not at all," "a little," "somewhat," "quite a bit," and "very much." The final question asks "if you were to spend the rest of your life with your dry mouth/throat dryness just the way it is now, how would you feel about this?" and includes options ranging from "delighted" to "terrible." All 15 questions can be translated to a score of 0-4, with a score of 4 indicating the most dry mouth-related problems and 0 indicating no dry mouth-related problems. | 12 months after baseline visit | |
Primary | Quality of life as assessed by the Xerostomia Quality of Life Scale (XeQoLS) | The XeQoLS consists of 15 questions. The first 14 questions assess how dryness in the mouth impacts the individual's life, with answer options of "not at all," "a little," "somewhat," "quite a bit," and "very much." The final question asks "if you were to spend the rest of your life with your dry mouth/throat dryness just the way it is now, how would you feel about this?" and includes options ranging from "delighted" to "terrible." All 15 questions can be translated to a score of 0-4, with a score of 4 indicating the most dry mouth-related problems and 0 indicating no dry mouth-related problems. | 24 months after baseline visit | |
Primary | Quality of life as assessed by the Xerostomia Quality of Life Scale (XeQoLS) | The XeQoLS consists of 15 questions. The first 14 questions assess how dryness in the mouth impacts the individual's life, with answer options of "not at all," "a little," "somewhat," "quite a bit," and "very much." The final question asks "if you were to spend the rest of your life with your dry mouth/throat dryness just the way it is now, how would you feel about this?" and includes options ranging from "delighted" to "terrible." All 15 questions can be translated to a score of 0-4, with a score of 4 indicating the most dry mouth-related problems and 0 indicating no dry mouth-related problems. | 30 months after baseline visit | |
Primary | Quality of life as assessed by the Oral Health Related Quality of Life (OHRQoL) | Oral health related quality of life will be assessed using the questionnaire developed for the National Health and Nutrition Examination Survey (NHANES). This questionnaire assesses the topic areas of last visit to dentist or lack of dental care; direct conversation with dental professional about your dental health; dental health perception; oral cancer exam; use of dental floss or dental rinse product; and periodontal disease self-report. Each topic area uses a separate scoring system and may be assessed individually. | Baseline | |
Primary | Quality of life as assessed by the Oral Health Related Quality of Life (OHRQoL) | Oral health related quality of life will be assessed using the questionnaire developed for the National Health and Nutrition Examination Survey (NHANES). This questionnaire assesses the topic areas of last visit to dentist or lack of dental care; direct conversation with dental professional about your dental health; dental health perception; oral cancer exam; use of dental floss or dental rinse product; and periodontal disease self-report. Each topic area uses a separate scoring system and may be assessed individually. | 12 months after baseline visit | |
Primary | Quality of life as assessed by the Oral Health Related Quality of Life (OHRQoL) | Oral health related quality of life will be assessed using the questionnaire developed for the National Health and Nutrition Examination Survey (NHANES). This questionnaire assesses the topic areas of last visit to dentist or lack of dental care; direct conversation with dental professional about your dental health; dental health perception; oral cancer exam; use of dental floss or dental rinse product; and periodontal disease self-report. Each topic area uses a separate scoring system and may be assessed individually. | 24 months after baseline visit | |
Primary | Quality of life as assessed by the Oral Health Related Quality of Life (OHRQoL) | Oral health related quality of life will be assessed using the questionnaire developed for the National Health and Nutrition Examination Survey (NHANES). This questionnaire assesses the topic areas of last visit to dentist or lack of dental care; direct conversation with dental professional about your dental health; dental health perception; oral cancer exam; use of dental floss or dental rinse product; and periodontal disease self-report. Each topic area uses a separate scoring system and may be assessed individually. | 30 months after baseline visit | |
Primary | Quality of life as assessed by the Tobacco, Alcohol, Prescription medication, and other Substance use (TAPS) Tool | The TAPS tool screens for substance use (including tobacco, alcohol, prescription medication, and other drugs) and includes a brief assessment of abuse risk for those who screen positive. Individuals who screen positive for use of any of the substances are then scored as 0 (no use in the past 3 months), 1 (problem use), and 2+ (high risk for substance use disorder). | Baseline | |
Primary | Quality of life as assessed by the Tobacco, Alcohol, Prescription medication, and other Substance use (TAPS) Tool | The TAPS tool screens for substance use (including tobacco, alcohol, prescription medication, and other drugs) and includes a brief assessment of abuse risk for those who screen positive. Individuals who screen positive for use of any of the substances are then scored as 0 (no use in the past 3 months), 1 (problem use), and 2+ (high risk for substance use disorder). | 12 months after baseline visit | |
Primary | Quality of life as assessed by the Tobacco, Alcohol, Prescription medication, and other Substance use (TAPS) Tool | The TAPS tool screens for substance use (including tobacco, alcohol, prescription medication, and other drugs) and includes a brief assessment of abuse risk for those who screen positive. Individuals who screen positive for use of any of the substances are then scored as 0 (no use in the past 3 months), 1 (problem use), and 2+ (high risk for substance use disorder). | 24 months after baseline visit | |
Primary | Quality of life as assessed by the Tobacco, Alcohol, Prescription medication, and other Substance use (TAPS) Tool | The TAPS tool screens for substance use (including tobacco, alcohol, prescription medication, and other drugs) and includes a brief assessment of abuse risk for those who screen positive. Individuals who screen positive for use of any of the substances are then scored as 0 (no use in the past 3 months), 1 (problem use), and 2+ (high risk for substance use disorder). | 30 months after baseline visit | |
Secondary | Xerostomia as assessed by stimulated saliva secretion rate | Prevalence of xerostomia | Baseline | |
Secondary | Xerostomia as assessed by stimulated saliva secretion rate | Prevalence of xerostomia | 6 months after baseline visit | |
Secondary | Xerostomia as assessed by stimulated saliva secretion rate | Prevalence of xerostomia | 12 months after baseline visit | |
Secondary | Xerostomia as assessed by stimulated saliva secretion rate | Prevalence of xerostomia | 18 months after baseline visit | |
Secondary | Xerostomia as assessed by stimulated saliva secretion rate | Prevalence of xerostomia | 24 months after baseline visit | |
Secondary | Xerostomia as assessed by stimulated saliva secretion rate | Prevalence of xerostomia | 30 months after baseline visit | |
Secondary | Saliva proteins | levels of amylase expression will be assessed | Baseline | |
Secondary | Saliva proteins | levels of amylase expression will be assessed | 6 months after baseline visit | |
Secondary | Saliva proteins | levels of amylase expression will be assessed | 12 months after baseline visit | |
Secondary | Saliva proteins | levels of amylase expression will be assessed | 18 months after baseline visit | |
Secondary | Saliva proteins | levels of amylase expression will be assessed | 24 months after baseline visit | |
Secondary | Saliva proteins | levels of amylase expression will be assessed | 30 months after baseline visit | |
Secondary | Saliva proteins | levels of IgA expression will be assessed | baseline visit | |
Secondary | Saliva proteins | levels of IgA expression will be assessed | 6 months after baseline visit | |
Secondary | Saliva proteins | levels of IgA expression will be assessed | 12 months after baseline visit | |
Secondary | Saliva proteins | levels of IgA expression will be assessed | 18 months after baseline visit | |
Secondary | Saliva proteins | levels of IgA expression will be assessed | 24 months after baseline visit | |
Secondary | Saliva proteins | levels of IgA expression will be assessed | 30 months after baseline visit | |
Secondary | Correlative measures | Salivary cytokines: levels of IL-6, IL-7, IL-10, TNF-a, neopterin, ß-2-microglobulin (ß2M) and monocyte chemotactic protein-1 will be assessed | Baseline through 30 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06162897 -
Case Management Dyad
|
N/A | |
Completed |
NCT03999411 -
Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients
|
Phase 4 | |
Completed |
NCT02528773 -
Efficacy of ART to Interrupt HIV Transmission Networks
|
||
Active, not recruiting |
NCT05454839 -
Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
|
||
Recruiting |
NCT05322629 -
Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women
|
N/A | |
Completed |
NCT02579135 -
Reducing HIV Risk Among Adolescents: Evaluating Project HEART
|
N/A | |
Active, not recruiting |
NCT01790373 -
Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence
|
N/A | |
Not yet recruiting |
NCT06044792 -
The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
|
||
Completed |
NCT04039217 -
Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM
|
Phase 4 | |
Active, not recruiting |
NCT04519970 -
Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK)
|
N/A | |
Completed |
NCT04124536 -
Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women
|
N/A | |
Recruiting |
NCT05599581 -
Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health
|
N/A | |
Active, not recruiting |
NCT04588883 -
Strengthening Families Living With HIV in Kenya
|
N/A | |
Completed |
NCT02758093 -
Speed of Processing Training in Adults With HIV
|
N/A | |
Completed |
NCT02500446 -
Dolutegravir Impact on Residual Replication
|
Phase 4 | |
Completed |
NCT03805451 -
Life Steps for PrEP for Youth
|
N/A | |
Active, not recruiting |
NCT03902431 -
Translating the ABCS Into HIV Care
|
N/A | |
Completed |
NCT00729391 -
Women-Focused HIV Prevention in the Western Cape
|
Phase 2/Phase 3 | |
Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
Recruiting |
NCT03589040 -
Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant
|
Phase 2 |